MEDINCELL SA (MEDCL.PA) Stock Price, Quote, News and Overview
EPA:MEDCL - Euronext Paris - Matif - FR0004065605 - Common Stock - Currency: EUR
MEDCL.PA Quote, Performance and Key Statistics
EPA:MEDCL (8/20/2025, 5:29:59 PM)
17.79
-0.01 (-0.06%)
The current stock price of MEDCL.PA is 17.79 EUR. In the past month the price increased by 13.88%. In the past year, price decreased by -1.66%.
MEDCL.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 44.05 | 576.98B | ||
| LLY.DE | ELI LILLY & CO | 43.02 | 563.43B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.01 | 422.13B | ||
| JNJ.DE | JOHNSON & JOHNSON | 17.92 | 369.49B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 17.24 | 355.37B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 13.86 | 234.52B | ||
| SAN.PA | SANOFI | 11.53 | 212.26B | ||
| SNW.DE | SANOFI | 11.45 | 210.90B | ||
| 1SAN.MI | SANOFI | 11.34 | 208.90B | ||
| NOT.DE | NOVARTIS AG-REG | 14.33 | 207.56B | ||
| NOV.DE | NOVO NORDISK A/S-B | 13.95 | 207.06B | ||
| 6MK.DE | MERCK & CO. INC. | 11.2 | 185.31B |
Related stock screener links
About MEDCL.PA
Company Profile
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 131 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Company Info
MEDINCELL SA
3 Rue des Freres Lumiere
Jacou OCCITANIE FR
Employees: 131
Phone: 33467021367
MEDINCELL SA / MEDCL.PA FAQ
What is the stock price of MEDINCELL SA today?
The current stock price of MEDCL.PA is 17.79 EUR. The price decreased by -0.06% in the last trading session.
What is the ticker symbol for MEDINCELL SA stock?
The exchange symbol of MEDINCELL SA is MEDCL and it is listed on the Euronext Paris - Matif exchange.
On which exchange is MEDCL.PA stock listed?
MEDCL.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for MEDINCELL SA stock?
16 analysts have analysed MEDCL.PA and the average price target is 23.59 EUR. This implies a price increase of 32.59% is expected in the next year compared to the current price of 17.79. Check the MEDINCELL SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MEDINCELL SA worth?
MEDINCELL SA (MEDCL.PA) has a market capitalization of 588.49M EUR. This makes MEDCL.PA a Small Cap stock.
How many employees does MEDINCELL SA have?
MEDINCELL SA (MEDCL.PA) currently has 131 employees.
What are the support and resistance levels for MEDINCELL SA (MEDCL.PA) stock?
MEDINCELL SA (MEDCL.PA) has a support level at 16.72 and a resistance level at 18.64. Check the full technical report for a detailed analysis of MEDCL.PA support and resistance levels.
Is MEDINCELL SA (MEDCL.PA) expected to grow?
The Revenue of MEDINCELL SA (MEDCL.PA) is expected to grow by 35.16% in the next year. Check the estimates tab for more information on the MEDCL.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MEDINCELL SA (MEDCL.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MEDCL.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MEDCL.PA, evaluating the profitability, health, valuation and growth aspects
- MEDINCELL SA (MEDCL.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MEDINCELL SA (MEDCL.PA) Sales and EPS estimates to see what analysts future expectations are.
- MEDINCELL SA (MEDCL.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MEDINCELL SA (MEDCL.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- MEDINCELL SA (MEDCL.PA) Stock Chart to make your own analysis
- MEDINCELL SA (MEDCL.PA) Latest news and press-releases to stay up to date.
Does MEDINCELL SA (MEDCL.PA) stock pay dividends?
MEDCL.PA does not pay a dividend.
When does MEDINCELL SA (MEDCL.PA) report earnings?
MEDINCELL SA (MEDCL.PA) will report earnings on 2025-12-09.
What is the Price/Earnings (PE) ratio of MEDINCELL SA (MEDCL.PA)?
MEDINCELL SA (MEDCL.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.08).
MEDCL.PA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MEDCL.PA. When comparing the yearly performance of all stocks, MEDCL.PA turns out to be only a medium performer in the overall market: it outperformed 43.62% of all stocks.
MEDCL.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MEDCL.PA. MEDCL.PA may be in some trouble as it scores bad on both profitability and health.
MEDCL.PA Financial Highlights
Over the last trailing twelve months MEDCL.PA reported a non-GAAP Earnings per Share(EPS) of -1.08. The EPS decreased by -6.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.43% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MEDCL.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to MEDCL.PA. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 141.86% and a revenue growth 35.16% for MEDCL.PA